Objective To study the association of neuregulin 1(NRG1)gene SNPrs2954041 polymorphisms with schizophrenia and cognitive function.Methods 70 psychiatric patients were selected as observation group, 70 healthy persons were selected as control group.NRG1 gene SNPrs2954041 polymorphism was detected,and the patients'cognitive function and neurological NSS score were evaluated.Results The differences of SNPrs2954041 polymorphism genotype and allele frequencies between the two groups were statistically significant(χ2 =35.412,29.341, all P =0.000).The differences in genotype and allele frequencies between the male observation patients and male control group were statistically significant(χ2 =24.571 ,18.391 ,all P =0.000).The differences in genotype and allelefrequencies between female the observation patients and female control group were statistically significant (χ2 =14.145,13.024,all P =0.000).The difference of memory understanding among the three groups was statistically sig-nificant(F =3.781,P =0.031).The difference of digit span,correct number,errors number,errors continued num-ber,non -sustained errors number in three groups showed no significant differences(F =0.702,0.125,0.089, 0.692,0.113,P =0.498,0.882,0.927,0.512,0.748),the difference of neurological soft signs score of T/T geno-type[(6.79 ±0.55)points],T/G genotype[(6.88 ±0.51 )points]and G/G genotype[(6.53 ±0.39)points]in schizophrenia group was not statistically significant(F =0.142,P =0.843).Conclusion NRG1 gene SNPrs2954041 polymorphism was related to schizophrenia and cognitive function in patients with schizophrenia.

Objective:To investigate the effect of clozapine on endocrine hormone levels in patients with schizophrenia, and to analyze the factors causing metabolic abnormality.Methods:The clinical data of 102 patients with schizophrenia who received treatment at the Wenzhou Seventh People's Hospital from January 2021 to January 2023 were retrospectively analyzed. All patients were treated with clozapine. They were divided into a normal metabolism group ( n = 76) and a metabolic abnormality group ( n = 26) according to whether or not metabolic abnormality occurred after treatment. The glycolipid metabolism levels, thyroid function, and gonadal hormone levels were recorded and compared between the two groups. Logistic regression analysis was then performed to determine the relevant factors influencing the occurrence of concurrent metabolic abnormality in these patients. Results:After treatment, the levels of triglyceride, low-density lipoprotein, glycosylated hemoglobin, triiodothyronine, and prolactin in patients were all significantly increased compared with those measured before treatment, while estradiol level was significantly decreased compared with that measured before treatment ( t = 2.84, 3.36, 25.35, 3.26, 4.88, -5.76, all P < 0.05). Body mass index, disease duration, and the levels of triglyceride, glycosylated hemoglobin, triiodothyronine, and prolactin in the metabolic abnormality group were significantly higher than those in the normal metabolism group, while the levels of low-density lipoprotein, FT 4, and estradiol in the metabolic abnormality group were significantly lower than those in the normal metabolism group ( t = 4.41, 5.67, 3.20, 4.71, 3.49, 3.97, -4.84, -4.51, -4.25, all P < 0.05). The results of the logistic regression analysis indicated that high body mass index ( OR = 7.410, 95% CI = 1.485-36.988), prolonged disease duration ( OR = 1.385, 95% CI = 1.088-1.764), low low-density lipoprotein level ( OR = 0.003, 95% CI = 0.000-0.453), elevated glycosylated hemoglobin level ( OR = 4.222, 95% CI = 1.067-16.706), decreased FT 4 level ( OR = 0.238, 95% CI = 0.086-0.655), and low estradiol level ( OR = 0.845, 95% CI = 0.726-0.984) were the factors associated with metabolic abnormality (all P < 0.05). Conclusion:The use of clozapine in the treatment of schizophrenia will affect the patient's glycolipid metabolism, thyroid function, and gonadal hormone levels. At the same time, it is found that high body mass index, long disease duration, low low-density lipoprotein level, high glycosylated hemoglobin level, low FT 4 level, and low estradiol level will increase the risk of metabolic abnormality in patients. Therefore, targeted interventions should be carried out according to the actual situation.